X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Making coupons count for patients with HIV

By Emilie Signora  |    August 8, 2022
Despite having insurance, too many patients with HIV face high out-of-pocket costs for brand medicines. This is largely driven by insurer-imposed barriers that shift the cost of life-saving care onto...   Read More

Myth vs. Fact: The Senate’s latest price setting proposal

By Nicole Longo  |    August 5, 2022
The narratives being built around the Senate’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t...   Read More

An open letter to Congress: Stand with patients and future cures

By Stephen J. Ubl  |    August 4, 2022
I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon their latest drug pricing proposal. You can read the letter here or below:   Read More

ICYMI: Patients across the country are sharing concerns about government price setting

By Matthew Norawong  |    August 3, 2022
As members of Congress continue to push forward misguided government price-setting policies under the guise of “negotiation,” patient advocates across the country have been speaking out in local...   Read More

The Senate’s latest price setting proposal will undermine U.S. economic growth

By Nicole Longo  |    August 3, 2022
Last week, we examined ways the latest drug pricing proposal will undermine patient access to medicines, American medical innovation and our health care system as a whole. But there is another...   Read More

Celebrating Medicare’s 57th anniversary

By Gabby Migliara  |    August 2, 2022
In case you missed it, Saturday, July 30, marked the anniversary of Medicare. For 57 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans...   Read More

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers

By Brian Newell  |    August 1, 2022
A new analysis by the health care analytics and research firm Avalere reveals the partisan drug pricing bill will have a much deeper impact on the biopharmaceutical research industry than previously...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates